SEC Filing Summary: ChromaDex Corp. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ChromaDex Corp. on September 22, 2014, reporting events occurring on September 19, 2014. The registrant is a Delaware corporation with principal executive offices in Irvine, California. The filing primarily addresses the entry into a material definitive agreement regarding intellectual property licensing.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a contractual agreement rather than periodic financial performance data.
Material Changes and Agreements
On September 19, 2014, ChromaDex, Inc. (a wholly owned subsidiary of the registrant) entered into a First Amendment to an Exclusive License Agreement with The Regents of the University of California (UC). Key terms include:
- Scope: UC granted ChromaDex a worldwide, exclusive, sublicensable right to use additional patent rights related to the compound Pterostilbene in a specified field of use.
- Compound Description: Pterostilbene is found in blueberries, grapes, other small fruits, and tree bark.
- Consideration: ChromaDex will make additional cash payments to UC, including annual license maintenance fees, earned royalties on net sales (subject to a minimum amount), milestone payments, and consideration for sublicensing.
- Termination: The agreement terminates upon the expiration of the last valid patent claim, failure to meet pre-development milestones, uncured default, or prior written notice by ChromaDex.
Guidance, Risks, and Unusual Items
The filing notes that certain terms of the agreement were sought under confidential treatment and will be detailed in the upcoming Form 10-Q for the quarter ended September 27, 2014. A press release announcing the amendment was issued on September 22, 2014. The filing does not contain forward-looking guidance, specific risk factors, or unusual items beyond the standard contractual obligations.
Investor Verification Checklist
- Verify the specific "specified field of use" for the Pterostilbene license, as this was not detailed in the 8-K.
- Review the upcoming Form 10-Q (for the quarter ended September 27, 2014) for the full text of the First Amendment and confidential terms.
- Confirm the specific amounts for annual maintenance fees, minimum royalty thresholds, and strategic milestone payments.
- Assess the impact of the new licensing fees on future cash flow and operating expenses.